Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter...
Multicenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity Weight loss of greater than 20% on par with...
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4 th Annual Healthcare Opportunities Conference, which...
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. ...
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter...
Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting...
In 522 patients, average weight loss was approximately 32 pounds at balloon passage and 31 pounds 1 year later, equating to approximately 95% weight maintenance ...
Allurion attributed the fall in Q4 revenue to a temporary suspension of sales in France, coupled with macroeconomic headwinds in certain markets, which caused lower reorder rates.
This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.
ALUR stock has more than tripled in value today as investors react to news of a GLP-1 study.